Ian McGowan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5492489/publications.pdf

Version: 2024-02-01

138 papers	6,432 citations	87723 38 h-index	71532 76 g-index
141 all docs	141 docs citations	141 times ranked	5704 citing authors

#	Article	IF	Citations
1	An Open-Label Pharmacokinetic and Pharmacodynamic Assessment of Tenofovir Gel and Oral Emtricitabine/Tenofovir Disoproxil Fumarate. AIDS Research and Human Retroviruses, 2022, 38, 279-287.	0.5	7
2	A Randomized, Open-Label, Crossover Phase 1 Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel (the CHARM-03 Study). AIDS Research and Human Retroviruses, 2022, 38, 269-278.	0.5	5
3	Acceptability of a Dapivirine/Placebo Gel Administered Rectally to HIV-1 Seronegative Adults (MTN-026). AIDS and Behavior, 2022, 26, 1333-1346.	1.4	4
4	Tofacitinib inhibits inflammatory cytokines from ulcerative colitis and healthy mucosal explants and is associated with pSTAT1/3 reduction in T-cells. American Journal of Physiology - Renal Physiology, 2021, 320, G396-G410.	1.6	6
5	Higher colorectal tissue HIV infectivity in cisgender women compared with MSM before and during oral preexposure prophylaxis. Aids, 2021, 35, 1585-1595.	1.0	10
6	Safety and Pharmacokinetics of a Tenofovir Alafenamide Fumarate-Emtricitabine based Oral Antiretroviral Regimen for Prevention of HIV Acquisition in Women: A Randomized Controlled Trial. EClinicalMedicine, 2021, 36, 100893.	3.2	27
7	Evaluation of the Safety, Acceptability, and Pharmacokinetic Profile of a Gel Formulation of OB-002 in Healthy Volunteers. AIDS Research and Human Retroviruses, 2021, 37, 453-460.	0.5	4
8	A Randomized, Double Blind, Placebo-Controlled, Phase 1 Safety and Pharmacokinetic Study of Dapivirine Gel (0.05%) Administered Rectally to HIV-1 Seronegative Adults (MTN-026). AIDS Research and Human Retroviruses, 2021, , .	0.5	5
9	Increases in HIV Incidence Following Receptive Anal Intercourse Among Women: A Systematic Review and Meta-analysis. AIDS and Behavior, 2020, 24, 667-681.	1.4	12
10	Treatment with Commonly Used Antiretroviral Drugs Induces a Type I/III Interferon Signature in the Gut in the Absence of HIV Infection. Cell Reports Medicine, 2020, 1, 100096.	3.3	10
11	Receptive anal sex contributes substantially to heterosexually acquired HIV infections among atâ€risk women in twenty US cities: Results from a modelling analysis. American Journal of Reproductive Immunology, 2020, 84, e13263.	1.2	11
12	Brief Report: Dipyridamole Decreases Gut Mucosal Regulatory T-Cell Frequencies Among People With HIV on Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 85, 665-669.	0.9	4
13	A Multiple Dose Phase 1 Assessment of Rilpivirine Long Acting in a Model of Preexposure Prophylaxis Against HIV. AIDS Research and Human Retroviruses, 2019, 35, 794-804.	0.5	5
14	The human tissue-resident CCR5 ⁺ T cell compartment maintains protective and functional properties during inflammation. Science Translational Medicine, 2019, 11, .	5.8	41
15	The pharmacokinetics, pharmacodynamics, and mucosal responses to maraviroc-containing pre-exposure prophylaxis regimens in MSM. Aids, 2019, 33, 237-246.	1.0	17
16	The Use of Droplet Digital PCR to Quantify HIV-1 Replication in the Colorectal Explant Model. AIDS Research and Human Retroviruses, 2019, 35, 326-334.	0.5	5
17	Prevalence and determinants of anal human papillomavirus infection in men who have sex with men and transgender women. International Journal of STD and AIDS, 2019, 30, 154-162.	0.5	20
18	Phase 2a Safety, Pharmacokinetics, and Acceptability of Dapivirine Vaginal Rings in US Postmenopausal Women. Clinical Infectious Diseases, 2019, 68, 1144-1151.	2.9	19

#	Article	IF	Citations
19	Comparative Assessment of Small and Large Intestine Biopsies forEx VivoHIV-1 Pathogenesis Studies. AIDS Research and Human Retroviruses, 2018, 34, 900-906.	0.5	4
20	A Pilot Study of the Immunologic, Virologic, and Pathologic Consequences of Intra-anal 5% Imiquimod in HIV-1â€"Infected Men With High-Grade Squamous Intraepithelial Lesions. Diseases of the Colon and Rectum, 2018, 61, 298-305.	0.7	4
21	Factors Supporting and Hindering Adherence to Rectal Microbicide Gel Use with Receptive Anal Intercourse in a Phase 2 Trial. AIDS and Behavior, 2018, 22, 388-401.	1.4	7
22	Brief Participant-Centered Convergence Interviews Integrate Self-Reports, Product Returns, and Pharmacokinetic Results to Improve Adherence Measurement in MTN-017. AIDS and Behavior, 2018, 22, 986-995.	1.4	9
23	Are participants concerned about privacy and security when using short message service to report product adherence in a rectal microbicide trial?. Journal of the American Medical Informatics Association: JAMIA, 2018, 25, 393-400.	2.2	11
24	Immunological responsiveness of intestinal tissue explants and mucosal mononuclear cells to ex vivo stimulation. Journal of Immunological Methods, 2018, 463, 39-46.	0.6	7
25	Does perâ€act <scp>HIV</scp>â€1 transmission risk through anal sex vary by gender? An updated systematic review and metaâ€analysis. American Journal of Reproductive Immunology, 2018, 80, e13039.	1.2	35
26	Pharmacokinetics and Pharmacodynamics of Tenofovir Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women: A Cross-Compartmental Study With Directly Observed Dosing. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 78, 175-182.	0.9	9
27	Ranpirnase Reduces HIV-1 Infection and Associated Inflammatory Changes in a Human Colorectal Explant Model. AIDS Research and Human Retroviruses, 2018, 34, 838-848.	0.5	8
28	MTN-017: A Rectal Phase 2 Extended Safety and Acceptability Study of Tenofovir Reduced-Glycerin 1% Gel. Clinical Infectious Diseases, 2017, 64, ciw832.	2.9	42
29	PHASE 2 STUDY OF THE SAFETY AND TOLERABILITY OF MARAVIROC-CONTAINING REGIMENS TO PREVENT HIV INFECTION IN MEN WHO HAVE SEX WITH MEN (MSM) (HPTN 069/ACTG A5305). Journal of Infectious Diseases, 2017, 215, jiw525.	1.9	40
30	Lessons for Rectal Microbicide Development From an Acceptability Trial of a Placebo Gel Applied Prior to Receptive Anal Intercourse. Archives of Sexual Behavior, 2017, 46, 1101-1109.	1.2	11
31	Stability of 5P12-RANTES, A Candidate Rectal Microbicide, in Human Rectal Lavage. AIDS Research and Human Retroviruses, 2017, 33, 768-777.	0.5	11
32	Analytical Advances in the Ex Vivo Challenge Efficacy Assay. AIDS Research and Human Retroviruses, 2017, 33, 395-403.	0.5	14
33	The Safety of Multiple Flexible Sigmoidoscopies with Mucosal Biopsies in Healthy Clinical Trial Participants. AIDS Research and Human Retroviruses, 2017, 33, 820-826.	0.5	8
34	Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women. Annals of Internal Medicine, 2017, 167, 384.	2.0	29
35	An ex vivo Model to Determine Stat Protein Phosphorylation in Human Colorectal Mononuclear Mucosal Cells Obtained From Biopsies. Gastroenterology, 2017, 152, S965-S966.	0.6	0
36	Preference of Oral Tenofovir Disoproxil Fumarate/Emtricitabine Versus Rectal Tenofovir Reduced-Glycerin 1% Gel Regimens for HIV Prevention Among Cisgender Men and Transgender Women Who Engage in Receptive Anal Intercourse with Men. AIDS and Behavior, 2017, 21, 3336-3345.	1.4	16

#	Article	IF	Citations
37	A Pilot Study of the Prevalence of Anal Human Papillomavirus and Dysplasia in a Cohort of Patients With IBD. Diseases of the Colon and Rectum, 2017, 60, 1307-1313.	0.7	13
38	High levels of adherence to a rectal microbicide gel and to oral Pre-Exposure Prophylaxis (PrEP) achieved in MTN-017 among men who have sex with men (MSM) and transgender women. PLoS ONE, 2017, 12, e0181607.	1.1	25
39	How common and frequent is heterosexual anal intercourse among South Africans? A systematic review and metaâ€analysis. Journal of the International AIDS Society, 2017, 20, 21162.	1.2	15
40	Rectal 1% Tenofovir Gel Use Associates with Altered Epidermal Protein Expression. AIDS Research and Human Retroviruses, 2016, 32, 1005-1015.	0.5	11
41	To Use a Rectal Microbicide, First Insert the Applicator: Gel and Applicator Satisfaction Among Young Men Who Have Sex With Men. AIDS Education and Prevention, 2016, 28, 1-10.	0.6	11
42	Acceptability of Three Novel HIV Prevention Methods Among Young Male and Transgender Female Sex Workers in Puerto Rico. AIDS and Behavior, 2016, 20, 2192-2202.	1.4	20
43	Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment. Lancet HIV,the, 2016, 3, e569-e578.	2.1	77
44	A Tunable, Biodegradable, Thin-Film Polymer Device as a Long-Acting Implant Delivering Tenofovir Alafenamide Fumarate for HIV Pre-exposure Prophylaxis. Pharmaceutical Research, 2016, 33, 1649-1656.	1.7	87
45	Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women. New England Journal of Medicine, 2016, 375, 2121-2132.	13.9	624
46	Distinct Pharmacodynamic Activity of Rilpivirine in Ectocervical and Colonic Explant Tissue. Antimicrobial Agents and Chemotherapy, 2016, 60, 2765-2770.	1.4	9
47	Influence of Partner Type on Acceptability and Likelihood of Use of a Rectal Microbicide Among Young Men Who Have Sex With Men in the United States and Puerto Rico. Journal of Sex Research, 2016, 53, 633-641.	1.6	16
48	Impact of Sex on the Pharmacokinetics and Pharmacodynamics of 1% Tenofovir Gel. Clinical Infectious Diseases, 2016, 62, 375-382.	2.9	20
49	Project Gel a Randomized Rectal Microbicide Safety and Acceptability Study in Young Men and Transgender Women. PLoS ONE, 2016, 11, e0158310.	1.1	14
50	Long-acting rilpivirine for HIV prevention. Current Opinion in HIV and AIDS, 2015, 10, 253-257.	1.5	41
51	Soluble Immune Mediators and Vaginal Bacteria Impact InnateÂGenital Mucosal Antimicrobial Activity in Young Women. American Journal of Reproductive Immunology, 2015, 74, 323-332.	1.2	14
52	Prevalence of Anal Human Papillomavirus Vaccine Types in the Bangkok Men Who Have Sex With Men Cohort Study. Sexually Transmitted Diseases, 2015, 42, 671-676.	0.8	13
53	A Phase 1 Randomized, Open Label, Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Three Formulations of Tenofovir 1% Gel (the CHARM-01 Study). PLoS ONE, 2015, 10, e0125363.	1.1	53
54	Exploring the Feasibility of Multi-Site Flow Cytometric Processing of Gut Associated Lymphoid Tissue with Centralized Data Analysis for Multi-Site Clinical Trials. PLoS ONE, 2015, 10, e0126454.	1.1	12

#	Article	IF	Citations
55	Protection Against Rectal Chimeric Simian/Human Immunodeficiency Virus Transmission in Macaques by Rectal-Specific Gel Formulations of Maraviroc and Tenofovir. Journal of Infectious Diseases, 2015, 212, 1988-1995.	1.9	26
56	Tenofovir-Based Preexposure Prophylaxis for HIV Infection among African Women. New England Journal of Medicine, 2015, 372, 509-518.	13.9	1,094
57	The Molecular Characterization of Intestinal Explant HIV Infection Using Polymerase Chain Reaction-Based Techniques. AIDS Research and Human Retroviruses, 2015, 31, 981-991.	0.5	8
58	HIV and mucosal barrier interactions: consequences for transmission and pathogenesis. Current Opinion in Immunology, 2015, 36, 22-30.	2.4	95
59	A Phase 1 Randomized, Blinded Comparison of the Pharmacokinetics and Colonic Distribution of Three Candidate Rectal Microbicide Formulations of Tenofovir 1% Gel with Simulated Unprotected Sex (CHARM-02). AIDS Research and Human Retroviruses, 2015, 31, 1098-1108.	0.5	20
60	Injectable and implantable antiretroviral strategies for HIV prevention. Future Virology, 2015, 10, 1163-1176.	0.9	9
61	Awareness of Post-Exposure Prophylaxis (PEP) and Pre-Exposure Prophylaxis (PrEP) Is Low but Interest Is High Among Men Engaging in Condomless Anal Sex With Men in Boston, Pittsburgh, and San Juan. AIDS Education and Prevention, 2015, 27, 289-297.	0.6	77
62	Variability of cytokine gene expression in intestinal tissue and the impact of normalization with the use of reference genes. Cytokine, 2015, 71, 81-88.	1.4	4
63	Mucosal effects of tenofovir 1% gel. ELife, 2015, 4, .	2.8	37
64	A Multi-Compartment Single and Multiple Dose Pharmacokinetic Comparison of Rectally Applied Tenofovir 1% Gel and Oral Tenofovir Disoproxil Fumarate. PLoS ONE, 2014, 9, e106196.	1.1	28
65	Sex Matters: MTN-011 Phase 1 Study on the Impact of Sex on Tenofovir Gel Pharmacokinetics (PK) and Pharmacodynamics (PD). AIDS Research and Human Retroviruses, 2014, 30, A38-A38.	0.5	1
66	A Phase 1 Evaluation of the Rectal Safety, Acceptability, Pharmacokinetics, and Pharmacodynamics of Three Formulations of Tenofovir 1% Gel. AIDS Research and Human Retroviruses, 2014, 30, A283-A284.	0.5	0
67	The Research Registry: A Valuable Strategy for Longitudinal Success in HIV Prevention Research Recruitment. AIDS Research and Human Retroviruses, 2014, 30, A173-A173.	0.5	0
68	A Phase 1 Open Label Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Intramuscular TMC278 LA (the MWRI-01 Study). AIDS Research and Human Retroviruses, 2014, 30, A71-A71.	0.5	4
69	Collaborative crafting in call centre teams. Journal of Occupational and Organizational Psychology, 2014, 87, 464-486.	2.6	70
70	Rectal Specific Gels Containing Maraviroc and/or Tenofovir Protect against Rectal SHIV Transmission in a Macaque Model. AIDS Research and Human Retroviruses, 2014, 30, A13-A14.	0.5	3
71	Proteomics Based Methods for Toxicity Monitoring of Rectal Microbicides. AIDS Research and Human Retroviruses, 2014, 30, A229-A229.	0.5	1
72	Humic Acids (HA) Strongly Potentiate Anti-HIV Effects of AZT, Griffithsin, and Cyanovirin. AIDS Research and Human Retroviruses, 2014, 30, A204-A204.	0.5	1

#	Article	IF	Citations
73	An Overview of Antiretroviral Preâ€Exposure Prophylaxis of <scp>HIV</scp> Infection. American Journal of Reproductive Immunology, 2014, 71, 624-630.	1.2	23
74	Performance of the Wisebagâ„¢ for Monitoring Daily Rectal Gel Application in Two Urban Cities in the United States. AIDS Research and Human Retroviruses, 2014, 30, A167-A168.	0.5	0
75	Preventing Drug Resistant HIV Infection in Colonic Tissue using Tenofovir and Maraviroc Combination Topical Rectal Gels. AIDS Research and Human Retroviruses, 2014, 30, A261-A262.	0.5	0
76	Adherence to Rectal Gel Use Among Mainly Ethnic Minority Young Men Who have Sex with Men During A 3-Month Placebo Gel Trial: Implications for Microbicide Research. AIDS and Behavior, 2014, 18, 1726-1733.	1.4	16
77	Rectal-Specific Microbicide Applicator: Evaluation and Comparison with a Vaginal Applicator Used Rectally. AIDS and Behavior, 2014, 18, 1734-1745.	1.4	18
78	Mucosal gene therapy using a pseudotyped lentivirus vector encoding murine interleukin-10 (mIL-10) suppresses the development and relapse of experimental murine colitis. BMC Gastroenterology, 2014, 14, 68.	0.8	12
79	The development of rectal microbicides for HIV prevention. Expert Opinion on Drug Delivery, 2014, 11, 69-82.	2.4	43
80	Interactive Voice Response System (IVRS): Data Quality Considerations and Lessons Learned During a Microbicide Placebo Adherence Trial With Young Men Who Have Sex With Men. Journal of Adolescent Health, 2014, 54, S57-S58.	1.2	1
81	Development of HIV-1 Rectal-Specific Microbicides and Colonic Tissue Evaluation. PLoS ONE, 2014, 9, e102585.	1.1	17
82	Correlation between Compartmental Tenofovir Concentrations and an Ex Vivo Rectal Biopsy Model of Tissue Infectibility in the RMP-02/MTN-006 Phase 1 Study. PLoS ONE, 2014, 9, e111507.	1.1	29
83	Use of a Novel Technology to Track Adherence to Product Use in a Microbicide Trial of Short Duration (MTN-007). AIDS and Behavior, 2013, 17, 3101-3107.	1.4	6
84	Rectal Microbicide Development. Current Topics in Microbiology and Immunology, 2013, 383, 117-136.	0.7	15
85	A Phase 1 Randomized, Double Blind, Placebo Controlled Rectal Safety and Acceptability Study of Tenofovir 1% Gel (MTN-007). PLoS ONE, 2013, 8, e60147.	1.1	89
86	Rectal Transmission of Transmitted/Founder HIV-1 Is Efficiently Prevented by Topical 1% Tenofovir in BLT Humanized Mice. PLoS ONE, 2013, 8, e60024.	1.1	54
87	The Motivations and Experiences of Young Women in a Microbicide Trial in the USA and Puerto Rico. World Journal of AIDS, 2013, 03, 179-186.	0.1	4
88	Variations in microbicide gel acceptability among young women in the USA and Puerto Rico. Culture, Health and Sexuality, 2012, 14, 151-166.	1.0	30
89	RMP-02/MTN-006: A Phase 1 Rectal Safety, Acceptability, Pharmacokinetic, and Pharmacodynamic Study of Tenofovir 1% Gel Compared with Oral Tenofovir Disoproxil Fumarate. AIDS Research and Human Retroviruses, 2012, 28, 1412-1421.	0.5	129
90	Dose-Response Relationship Between Tissue Concentrations of UC781 and Explant Infectibility with HIV Type 1 in the RMP-01 Rectal Safety Study. AIDS Research and Human Retroviruses, 2012, 28, 1422-1433.	0.5	44

#	Article	IF	Citations
91	Nonreproducibility of â€œSnap-Frozenâ€•Rectal Biopsies for Later Use in Ex Vivo Explant Infectibility Studies. AIDS Research and Human Retroviruses, 2012, 28, 1509-1512.	0.5	18
92	Rectal microbicide development. Current Opinion in HIV and AIDS, 2012, 7, 526-533.	1.5	17
93	Successes and challenges of HIV prevention in men who have sex with men. Lancet, The, 2012, 380, 388-399.	6.3	349
94	â€œTell Julianaâ€: Acceptability of the Candidate Microbicide VivaGelÂ® and Two Placebo Gels Among Ethnically Diverse, Sexually Active Young Women Participating in a Phase 1 Microbicide Study. AIDS and Behavior, 2012, 16, 1761-1774.	1.4	40
95	Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004). Aids, 2011, 25, 1057-1064.	1.0	108
96	Rectal Microbicides: Can We Make Them and Will People Use Them?. AIDS and Behavior, 2011, 15, 66-71.	1.4	61
97	Protection of HIV Neutralizing Aptamers against Rectal and Vaginal Nucleases. Journal of Biological Chemistry, 2011, 286, 2526-2535.	1.6	30
98	Colorectal microbicide design. Aids, 2011, 25, 1971-1979.	1.0	39
99	First Phase 1 Double-Blind, Placebo-Controlled, Randomized Rectal Microbicide Trial Using UC781 Gel with a Novel Index of Ex Vivo Efficacy. PLoS ONE, 2011, 6, e23243.	1.1	79
100	Youth-Specific Considerations in the Development of Preexposure Prophylaxis, Microbicide, and Vaccine Research Trials. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 54, S31-S42.	0.9	25
101	Microbicides for HIV prevention: reality or hope?. Current Opinion in Infectious Diseases, 2010, 23, 26-31.	1.3	64
102	Acceptability of UC781 Gel as a Rectal Microbicide Among HIV-Uninfected Women and Men. AIDS and Behavior, 2010, 14, 618-628.	1.4	34
103	Advances in the Development of Microbicides for the Prevention of HIV Infection. Current Infectious Disease Reports, 2010, 12, 56-62.	1.3	24
104	Effective in vivo and ex vivogene transfer to intestinal mucosa by VSV-G-pseudotyped lentiviral vectors. BMC Gastroenterology, 2010, 10, 44.	0.8	18
105	Heterosexual Anal Intercourse Has the Potential to Cause a Significant Loss of Power in Vaginal Microbicide Effectiveness Studies. Sexually Transmitted Diseases, 2010, 37, 361-364.	0.8	30
106	Heterosexual anal intercourse has the potential to cause a significant loss of power in vaginal microbicide effectiveness studies. Sexually Transmitted Diseases, 2010, 37, 361-4.	0.8	28
107	Reverse Transcriptase Inhibitors as Potential Colorectal Microbicides. Antimicrobial Agents and Chemotherapy, 2009, 53, 1797-1807.	1.4	77
108	Microbicides. , 2009, , 85-106.		1

#	Article	IF	Citations
109	An aptamer that neutralizes R5 strains of HIV-1 binds to core residues of gp120 in the CCR5 binding site. Virology, 2008, 381, 46-54.	1.1	52
110	Rectal microbicides: a new focus for HIV prevention. Sexually Transmitted Infections, 2008, 84, 413-417.	0.8	33
111	Prevention of SIV Rectal Transmission and Priming of T Cell Responses in Macaques after Local Pre-exposure Application of Tenofovir Gel. PLoS Medicine, 2008, 5, e157.	3.9	159
112	Rectal microbicides. Current Opinion in HIV and AIDS, 2008, 3, 593-598.	1.5	8
113	Characterization of Baseline Intestinal Mucosal Indices of Injury and Inflammation in Men for Use in Rectal Microbicide Trials (HIV Prevention Trials Network-056). Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 46, 417-425.	0.9	45
114	HIV-1 pathogenesis differs in rectosigmoid and tonsillar tissues infected ex vivo with CCR5- and CXCR4-tropic HIV-1. Aids, 2007, 21, 1263-1272.	1.0	60
115	Ex vivo culture of human colorectal tissue for the evaluation of candidate microbicides. Aids, 2006, 20, 1237-1245.	1.0	122
116	Lack of Decay of HIV-1 in Gut-Associated Lymphoid Tissue Reservoirs in Maximally Suppressed Individuals. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 43, 65-68.	0.9	115
117	Microbicides 2006 conference. AIDS Research and Therapy, 2006, 3, 25.	0.7	12
118	Microbicides: A new frontier in HIV prevention. Biologicals, 2006, 34, 241-255.	0.5	72
119	Modeling the potential impact of rectal microbicides to reduce HIV transmission in bathhouses. Mathematical Biosciences and Engineering, 2006, 3, 459-466.	1.0	16
120	Binding and Transfer of Human Immunodeficiency Virus by DC-SIGN+ Cells in Human Rectal Mucosa. Journal of Virology, 2005, 79, 5762-5773.	1.5	108
121	Increased HIV-1 Mucosal Replication Is Associated With Generalized Mucosal Cytokine Activation. Journal of Acquired Immune Deficiency Syndromes (1999), 2004, 37, 1228-1236.	0.9	95
122	Intestinal mucosal CCR5 expression is down-regulated in HIV infection. Gastroenterology, 2003, 124, A155.	0.6	0
123	The IL-10/IL-12 axis and regulation of DC-SIGN expression in HIV-infected human gut mucosa. Gastroenterology, 2003, 124, A155-A156.	0.6	0
124	Extended Treatment With Tenofovir Disoproxil Fumarate in Treatment-Experienced HIV-1â€“Infected Patients: Genotypic, Phenotypic, and Rebound Analyses. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 33, 15-21.	0.9	60
125	Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF. Aids, 2002, 16, 1227-1235.	1.0	136
126	HIV-related diarrhea is multifactorial and fat malabsorption is commonly present, independent of HAART. American Journal of Gastroenterology, 2001, 96, 1831-1837.	0.2	53

#	Article	IF	Citations
127	Phase I/II Trial of the Pharmacokinetics, Safety, and Antiretroviral Activity of Tenofovir Disoproxil Fumarate in Human Immunodeficiency Virus-Infected Adults. Antimicrobial Agents and Chemotherapy, 2001, 45, 2733-2739.	1.4	319
128	Hydroxyurea Does Not Enhance the Anti-HIV Activity of Low-Dose Tenofovir Disoproxil Fumarate. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 28, 336-339.	0.9	7
129	Sensitive and reproducible quantitation of mucosal HIV-1 RNA and DNA viral burden in patients with detectable and undetectable plasma viral HIV-1 RNA using endoscopic biopsies. Journal of Virological Methods, 2001, 95, 65-79.	1.0	21
130	Enhanced levels of functional HIV-1 co-receptors on human mucosal T cells demonstrated using intestinal biopsy tissue. Aids, 2000, 14, 1761-1765.	1.0	153
131	Mucosal Substance P Receptor Expression in HIV Infection and Inflammatory Bowel Disease. NeuroImmunoModulation, 1997, 4, 70-76.	0.9	12
132	AIDS and intestinal disease. Current Opinion in Gastroenterology, 1997, 13, 18-23.	1.0	2
133	ADVANCES IN MUCOSAL IMMUNOLOGY. Gastroenterology Clinics of North America, 1997, 26, 145-173.	1.0	11
134	HHV8 DNA in normal gastrointestinal mucosa from HIV seropositive people. Lancet, The, 1996, 347, 1337-1338.	6.3	28
135	Cytokine gene transcription of human colonic intraepithelial lymphocytes costimulated with epithelial cells bearing HLA-DR and its inhibition by 5-aminosalicylic acid. Journal of Clinical Immunology, 1996, 16, 237-241.	2.0	9
136	Cytokine gene expression in HIV-infected intestinal mucosa. Aids, 1994, 8, 1569-1576.	1.0	56
137	Intestinal mucosal abnormality associated with human immunodeficiency virus infection. European Journal of Gastroenterology and Hepatology, 1994, 6, 813-820.	0.8	4
138	Palliative laser therapy for inoperable rectal cancerâ€“does it work?. A prospective study of quality of life. Cancer, 1989, 63, 967-969.	2.0	40